Slowing the Progression of Vascular Calcification in Hemodialysis
|
|
- Melina Johnson
- 5 years ago
- Views:
Transcription
1 Slowing the Progression of Vascular Calcification in Hemodialysis J Am Soc Nephrol 14: S310 S314, 2003 GLENN M. CHERTOW Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California Abstract. Hyperphosphatemia and secondary hyperparathyroidism are common complications of ESRD (chronic kidney disease stage 5) that, when untreated, may result in increased morbidity and mortality. Hyperphosphatemia and hypercalcemia have been associated with increased coronary artery calcification. Achieving control of serum phosphorus without increasing serum calcium is an important goal for patients with ESRD. Although calcium-based phosphate binders effectively reduce serum phosphorus and parathyroid hormone concentrations, these agents can lead to hypercalcemia and have been associated with increased vascular calcification. The phosphorus binder sevelamer was developed to overcome the limitations associated with the usual management of hyperphosphatemia and secondary hyperparathyroidism (i.e., mineral salts). Sevelamer, a nonabsorbable hydrogel, is as efficacious as calcium-based phosphate binders for reducing serum phosphorus but does not cause hypercalcemia or other adverse metabolic effects. Sevelamer also exhibits beneficial effects on lipids, consistently and significantly decreasing LDL cholesterol and increasing HDL cholesterol in most studies. In a head-to-head randomized clinical trial, sevelamer and calciumbased binders achieved similarly excellent phosphorus control, but the use of calcium-based binders led to significantly higher serum calcium concentrations and an increased incidence of hypercalcemia and unintended suppression of parathyroid hormone. Treatment with calcium-based binders also led to the progression of coronary artery and aortic calcification, whereas sevelamer attenuated or arrested progression. Strategies that use oral calcium and vitamin D in patients with ESRD should be reexamined, and the potential advantages of sevelamer should be considered when selecting a primary agent to reduce serum phosphorus in hemodialysis patients. Hyperphosphatemia and secondary hyperparathyroidism (HPT) are common complications of end-stage renal disease (ESRD) (1). Untreated secondary HPT can lead to significant morbidity as a result of pain, pruritus, bone loss, increased fracture risk, and anemia (2,3) and can contribute to heart disease and hypertension (4,5). Management of hyperphosphatemia and secondary HPT in patients with ESRD is critical, because cardiovascular disease is the leading cause of death in this patient population (6). Annual cardiovascular mortality rates are several-fold higher in patients with ESRD than in the general population, even when adjusted for age, gender, race, and the presence of diabetes. In addition to traditional risk factors (age, gender, race, diabetes, hypertension, lifestyle factors, smoking, lipids, hyperhomocysteinemia), inflammation, oxidative stress as a result of uremia and/or dialysis, and disorders of mineral metabolism may contribute to cardiovascular disease in patients with ESRD (7,8). In particular, disorders of mineral metabolism may contribute to cardiac calcification, which may in turn Correspondence to Dr. Glenn M. Chertow, Department of Medicine Research, University of California at San Francisco, UCSF Laurel Heights Suite 430, 3333 California Street, San Francisco, CA Phone: ; Fax: ; chertowg@medicine.ucsf.edu / Journal of the American Society of Nephrology Copyright 2003 by the American Society of Nephrology DOI: /01.ASN increase the risk of cardiovascular disease and mortality. Individuals who are on dialysis are prone to severe calcification (9,10), and a correlation has been demonstrated between the degree of coronary calcification and the prevalence of overt atherosclerotic vascular disease (11). These results are in agreement with those of Blacher et al. (12), who demonstrated that in hemodialysis patients, the probability of all-cause mortality increased with increasing calcification score using B- mode ultrasound. Hyperphosphatemia is associated with elevated cardiovascular risk and mortality (13 16). Analysis of data from the United States Renal Data System demonstrated an association between elevated phosphorus and calcium-phosphorus product and mortality (15), and a follow-up analysis indicated that hyperphosphatemia was associated with cause-specific cardiovascular death (16). These adverse effects of hyperphosphatemia are thought to be linked to the ability of phosphate to enhance vascular calcification (14,16), although the exact mechanism(s) is unknown. Data from Giachelli in this supplement (17) suggest that the mechanism is more complex than the traditional theory of passive crystallization and tissue deposition. Hyperphosphatemia and HPT: Treatment Options Several treatment options, either alone or in combination, are available for the treatment of hyperphosphatemia and secondary HPT in patients with ESRD (Table 1). The duration and
2 J Am Soc Nephrol 14: S310 S314, 2003 Vascular Calcification in Hemodialysis S311 Table 1. Treatment options for hyperphosphatemia and hyperparathyroidism Adjustment of dialysis duration and frequency Dietary restriction Oral or intravenous administration of vitamin D metabolites Oral phosphate binders aluminum salts calcium salts magnesium salts sevelamer frequency of dialysis may be adjusted to normalize phosphorus levels; nocturnal hemodialysis with long treatment times seems to be most effective (18). Dietary phosphorus restriction can be applied, although the need for adequate dietary protein limits this approach, and with conventional dialysis a phosphate binder is almost always required. Oral or intravenous administration of vitamin D metabolites can correct secondary HPT (19) but leads to enhanced intestinal absorption of calcium and phosphorus and, in doing so, may indirectly contribute to vascular calcification. Aluminum, magnesium, and calcium salts have also been used to bind dietary phosphorus. Aluminum salts can lead to osteomalacia, anemia, and, in rare cases, encephalopathy (20,21). Most physicians advise against the routine use of aluminum because of the side effects associated with its accumulation. Magnesium salts are infrequently used, being dose limited by gastrointestinal side effects (22). Calcium salts tend to be well tolerated in most individuals and can effectively bind intestinal phosphorus. During the late 1980s and the 1990s, calcium salts became the conventional strategy for controlling hyperphosphatemia. However, a variable fraction of the calcium can be absorbed, depending in part on co-administration of vitamin D and other gastrointestinal factors (e.g., gastric ph, timing of administration, meal content, other medications). Moreover, despite more intensive dialysis, dietary phosphorus restriction, and treatment with calcium- and aluminum-based phosphate binders, more than 60% of hemodialysis patients have suboptimal control of calcium and phosphorus, and others experience persistent elevations of parathyroid hormone (PTH) or require parathyroidectomy to achieve adequate phosphorus control (23). The phosphate binder sevelamer (Renagel; Genzyme, Cambridge, MA) was developed and introduced in 1998 to overcome the limitations associated with traditional management of hyperphosphatemia and secondary HPT. Sevelamer is a non calcium-, non aluminum-containing hydrogel that is resistant to digestive degradation and is not absorbed from the gastrointestinal tract (23). Sevelamer Hydrochloride Short-Term Studies Several short-term studies have shown sevelamer to be as efficacious as calcium acetate or calcium carbonate in decreasing serum phosphorus concentrations (24 29). Moreover, results indicate that sevelamer is well tolerated and provides adequate control of HPT without increasing serum calcium, even when used in conjunction with vitamin D metabolites. In short-term studies, sevelamer consistently reduced PTH (25,29). Furthermore, maintenance of target PTH concentrations in sevelamer-treated subjects was accomplished, often with the addition of vitamin D metabolites (30). Sevelamer also leads to significant decreases in the calcium-phosphorus product (23). Compared with calcium salts, sevelamer may lead to reductions in serum bicarbonate, on the order of 2 to 3 meq/l, in part as a result of the withdrawal of acetate or carbonate anions from previous binder usage. In addition, sevelamer has been shown to induce small but statistically significant reductions in serum uric acid concentration (31). Unique among phosphate binders, sevelamer has favorable effects on the lipid profile, consistently decreasing LDL cholesterol by more than 30% and increasing HDL cholesterol by 5 to 15% in most studies (23 27,29). Long-Term Studies Recent long-term studies have evaluated the safety and efficacy of sevelamer in hemodialysis patients (23,32). The long-term efficacy of open-label sevelamer was evaluated over a 46-wk period in 192 adult hemodialysis patients (23). Sevelamer significantly decreased serum phosphorus (mean decrease, mg/dl) and calcium-phosphorus product (mean decrease, mg 2 /dl 2 ) and overall led to no significant changes in PTH at 1 yr. A small but statistically significant increase in serum calcium was observed with sevelamer treatment that was independent of dose, although the average incidence of hypercalcemia (defined in this study as 11 mg/dl) was less than 2%. A single long-term, randomized, clinical trial ( treat to goal ) compared sevelamer with calcium-based phosphate binders in 200 hemodialysis patients at 15 sites in the United States and Europe (32). The subjects were randomized to 1 yr of open-label treatment with sevelamer or calcium salts (acetate in the United States and carbonate in Europe). Patients were eligible for study participation when they were hyperphosphatemic ( 5.5 mg/dl) after a 1- to 2-wk phosphate binder washout period. Target values for serum phosphorus were more ambitious (3.0 to 5.0 mg/dl) than in other studies. Target values for serum calcium (adjusted for albumin) were 8.5 to 10.5 mg/dl and for PTH were 150 to 300 pg/ml. In addition to evaluating the comparative effects of sevelamer and calcium salts on parameters of mineral metabolism, we tested the hypothesis that sevelamer and calcium salts would have differential effects on vascular calcification. In evaluating coronary and aortic calcification, electron beam tomography (EBT) was performed at baseline, 6 mo, and 1 yr. Subjects who were treated with sevelamer and calcium achieved excellent phosphorus control (end of treatment serum phosphorus for both groups, 5.1 mg/dl; Figure 1). The use of calcium-based binders led to significantly higher serum calcium concentrations (P 0.002; Figure 2) and a higher incidence of hypercalcemia (P 0.04; defined in this study as an adjusted serum calcium 10.5 mg/dl; Figure 3). These changes were attenuated during the study by the reduction or discon-
3 S312 Journal of the American Society of Nephrology J Am Soc Nephrol 14: S310 S314, 2003 Figure 1. Serum phosphorus response to calcium-containing versus non calcium-containing (sevelamer) phosphate binders. Figure 3. Hypercalcemia ( 10.5 mg/dl) for calcium-containing versus non calcium-containing (sevelamer) phosphate binders. Figure 2. Serum calcium response to calcium-containing versus non calcium-containing (sevelamer) phosphate binders. Figure 4. Serum intact parathyroid hormone response to calcium-containing versus non calcium-containing (sevelamer) phosphate binders. tinuation of vitamin D, reduction in dialysate calcium, and the use of rescue aluminum hydroxide in some calcium-treated subjects, all provided for by the study protocol for safety considerations. Subjects who were treated with calcium-based binders experienced significant unintentional suppression of PTH with median values below 150 pg/ml at all on-treatment time points compared with sevelamer-treated subjects, whose median PTH concentrations remained within the target range (Figure 4). Even transient hypercalcemia with calcium-based phosphate binders may be undesirable. Guérin et al. (33) showed a significant relation between vascular calcification by B-mode ultrasonography and episodes of hypercalcemia (8%, 10%, 18%, 36%, and 42% in patients with 0, 1, 2, 3, or 4 sites of calcification, respectively; P 0.034). Several investigators have shown PTH concentrations below 150 pg/ml to be associated with low bone turnover and an increased rate of fractures and extraskeletal calcification (34,35). Atherosclerotic vascular disease is significantly associated with the coronary artery calcification score by EBT in the general population (36 38) and in people with uremia (11). In hemodialysis patients, correlates of the extent of coronary calcification were advanced age, male gender, white race, diabetes, and longer vintage; calcium and phosphorus were the only modifiable risk factors. We found a 1.0-mg/dl higher serum phosphorus and a 0.5-mg/dl higher serum calcium to be associated with the same relative increase in vascular calcification as 2.5 yr of dialysis. There were no associations between the extent of coronary artery calcification and serum albumin, hemoglobin, and lipid parameters. Therefore, the favorable metabolic effects of sevelamer might be expected to reduce the extent of coro-
4 J Am Soc Nephrol 14: S310 S314, 2003 Vascular Calcification in Hemodialysis S313 nary artery calcification and potentially reduce the risk of overt coronary heart disease. In the treat-to-goal study, baseline EBT scores were extremely high (93rd percentile for age- and gender-matched normal subjects) and were nominally higher in the subjects who were randomized to sevelamer (although not significantly different) (32). However, the mean and median nominal change, mean and median percentage change, and mean and median weekly trend scores were significantly higher in calcium-treated subjects. In other words, the difference in vascular calcification was evident regardless of the method of data analysis. Given a median zero nominal change in coronary and aortic calcification in sevelamer-treated subjects, an equal number of subjects experienced regression as progression over the 1-yr study. Non Calcium-Based Versus Calcium-Based Phosphate Binders: A Comparative Overview Evidence suggests that sevelamer would provide considerable benefits over calcium salts as primary therapy for hyperphosphatemia. The treat-to-goal study demonstrated that in achieving satisfactory phosphorus control using calcium salts, a high frequency of unacceptable metabolic side effects can be anticipated. Indeed, the frequency of hypercalcemia and the more pronounced degree of PTH lowering seen in calciumtreated subjects in the treat-to-goal study reflect the ambitious phosphorus targets. Therefore, even in the absence of cardiovascular benefits, sevelamer would be preferred for its metabolic effects on bone. The exact mechanism(s) for progressive vascular calcification in hemodialysis patients is unknown. An increasing incidence of cardiovascular disease and other disorders of calcification (e.g., uremic calcific arteriolopathy) over the past decade has been attributed in part to the widespread use of oral calcium and vitamin D metabolites. Possible reasons for a protective vascular effect of sevelamer include improved metabolic control; differences in calcium load; and differential effects on bone dynamics, lipids, and inflammation. Calcium-based phosphate binders increase calcium load. Several studies have linked the dose of oral calcium with vascular calcification. Goodman et al. (10) showed that adolescents and young adults who were on dialysis and had evidence of coronary artery calcification were prescribed nearly twice the dose of oral calcium carbonate as patients without calcification (mean, 6456 versus 3325 mg; P 0.02). Guérin et al. (33) showed a direct correlation between prescribed oral calcium and the number of sites of vascular calcification (1.35, 1.35, 1.50, 1.84, and 2.18 g elemental calcium in patients with 0, 1, 2, 3, and 4 sites of calcification, respectively; P 0.001). We cannot determine whether the beneficial effects on lipids induced by sevelamer contributed to the benefit on vascular calcification. In the treat-to-goal study, mean LDL cholesterol (71 versus 108 mg/dl; P 0.001), mean apolipoprotein B (63 versus 84 mg/dl; P ), and median homocysteine (19.3 versus 29.7 mol/l; P 0.04) concentrations were significantly lower in sevelamer-treated subjects than in subjects who received calcium-based phosphate binders. Finally, differential effects of sevelamer and calcium-based phosphate binders on inflammation may contribute to differences in coronary calcification. Chronic inflammation is commonly observed in patients with ESRD (39), and markers of inflammation have been associated with coronary calcification in these patients (33). It has been hypothesized that inflammation may trigger arterial calcium deposition in dialysis patients, particularly at the end of the dialysis session, when back-filtration is most likely to occur and the plasma is maximally alkalinized (40). Further studies are needed to investigate the effects of sevelamer and calcium-based phosphate binders on markers of inflammation, such as C-reactive protein and fibrinogen, and to examine the relation between changes in these markers and changes in coronary calcification. Conclusion Hyperphosphatemia has been recognized as a key modifiable risk factor in patients who are on hemodialysis. As target values for serum phosphorus and the calcium phosphorus product have been reduced (e.g., Kidney Disease Outcomes Quality Initiative guidelines of 5.5 mg/dl and 55 mg 2 /dl 2, respectively [National Kidney Foundation, unpublished review, 2003]), the need for improved phosphate binders has become even more pronounced. As the dose of calcium-based phosphate binders increases, so does the frequency of hypercalcemia, and excessive calcium intake can lead to adynamic (low turnover) bone disease. In contrast, sevelamer can be titrated safely with no metal absorption. Changes in vascular calcification are provocative. Additional studies are under way to examine the relative effects of sevelamer and calcium-based phosphate binders on mortality and cardiovascular events. For now, practitioners should use calcium-based phosphate binders cautiously. With ongoing evidence, non calcium-containing phosphate binders may soon evolve into first-line therapies for dialysis-related hyperphosphatemia. References 1. Takamoto S, Onishi T, Morimoto S, Imanaka S, Tsuchiya H, Seino Y, Yokokawa T, Iida N, Kumahara Y: Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: Effect of aluminum hydroxide administration. Nephron 40: , Massry SG, Goldstein DA: Role of parathyroid hormone in uremic toxicity. Kidney Int Suppl 8: S39 S42, Gonzalez EA, Martin KJ: Renal osteodystrophy: Pathogenesis and management. Nephrol Dial Transplant 10[Suppl 3]: 13 21, Fliser D, Franek E, Fode P, Stefanski A, Schmitt CP, Lyons M, Ritz E: Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 12: , Nishizawa Y, Shoji T, Kawagishi T, Morii H: Atherosclerosis in uremia: Possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl 62: S90 S92, Foley RN, Parfrey PS, Sarnak MI: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kid Dis 32[Suppl 3]: S112 S119, 1998
5 S314 Journal of the American Society of Nephrology J Am Soc Nephrol 14: S310 S314, Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: , Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: , Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: , Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: , Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients: A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: , Blacher J, Guérin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: , Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35: , Block GA: Control of serum phosphorus: Implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 10: , Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: , Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO 4,Ca PO 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: , Giachelli CM: Vascular calcification: In vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14[Suppl]: S300 S304, Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53: , Drüeke TB: Control of secondary hyperparathyroidism by vitamin D derivatives. Am J Kidney Dis 37[Suppl 2]: S58 S61, Kates DM, Andress DL: Control of hyperphosphatemia in renal failure: Role of aluminum. Semin Dial 9: , Delmez JA, Slatopolsky E: Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19: , Durlach J, Durlach V, Bac P, Bara M, Guiet-Bara A: Magnesium and therapeutics. Magnes Res 7(3 4): , Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long-term effects of sevelamer hydrochloride on the calcium phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 14: , Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E: Poly[allylamine hydrochloride] (Renagel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29: 66 71, Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK: Effect of Renagel, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphate, calcium and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 13: , Wilkes BM, Reiner D, Kern M, Burke S: Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (Renagel) in dialysis patients. Clin Nephrol 50: , Bleyer AJ, Burke SK, Dillon MM, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33: , Chertow GM, Dillon M, Burke SK, Steg M, Blyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51: 18 26, Slatopolsky EA, Burke SK, Dillon MA: Renagel, a nonabsorbed, calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone: The Renagel Study Group. Kidney Int 55: , Chertow GM, Lowrie EG, Lew NL, Lazarus JM: Mineral metabolism and mortality in hemodialysis [Abstract]. JAmSoc Nephrol 11: 560A, Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M: RenaGel efficacy in severe secondary hyperparathyroidism. Nefrologia 22: , Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: , Guérin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: , Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A: A novel mechanism for skeletal resistance in uremia. Kidney Int 58: , Panuccio V, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Asahi K, Miyata T, Zoccali C: Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis 40: , Arad Y, Spadaro LA, Goodman K, Lledo-Perez A, Sherman S, Lerner G, Guerci AD: Predictive value of electron beam computed tomography of the coronary arteries: 19-month follow-up of 1173 asymptomatic subjects. Circulation 93: , Redberg RF, Shaw LJ: A review of electron beam computed tomography: Implications for coronary artery disease screening. Prev Cardiol 5: 71 78, Rumberger JA, Brundage BH, Rader DJ, Kondos G: Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons. Mayo Clin Proc 74: , Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: Sources, consequences, and therapy. Semin Dial 15: , Brancaccio D, Tetta C, Gallieni M, Panichi V: Inflammation CRP, calcium overload and a high calcium-phosphate product: A liaison dangereuse. Nephrol Dial Transplant 17: , 2002
The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationSevelamer hydrochloride: a calcium- and metal-free phosphate binder
DRUG PROFILE Sevelamer hydrochloride: a calcium- and metal-free phosphate binder Anthony J Bleyer & James Balwit Author for correspondence Wake Forest University School of Medicine, Section on Nephrology,
More informationOriginal epidemiologic studies 1 have suggested that approximately
Factors for Increased Morbidity and Mortality in Uremia: Hyperphosphatemia Nathan W. Levin, Frank A. Gotch, and Martin K. Kuhlmann Hyperphosphatemia is a metabolic abnormality present in the majority of
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationHyperphosphatemia is associated with a
TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular
More informationTreatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)
Kidney International, Vol. 65 (2004), pp. 1914 1926 Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study) WAJEH Y. QUNIBI,ROBERT E. HOOTKINS,LAVETA
More informationA new era in phosphate binder therapy: What are the options?
http://www.kidney-international.org & 2006 International Society of Nephrology A new era in phosphate binder therapy: What are the options? IB Salusky 1 1 Department of Pediatrics, David Geffen School
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEffectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients
Open Access Journal of Journal of Parathyroid Disease 2017,5(1),17 24 http://www.jparathyroid.com Original Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationEffect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
Research Article Effect of lanthanum and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease P. Thomas Scaria, Reneega Gangadhar 1, Ramdas Pisharody 2 ABSTRACT Departments
More informationCost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients
original article http://www.kidney-international.org & 2007 International Society of Nephrology Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis
More informationAssociation of Elevated Serum PO 4,Ca PO 4 Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis Patients
J Am Soc Nephrol 12: 2131 2138, 2001 Association of Elevated Serum PO 4,Ca PO 4 Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis Patients SANTHI K. GANESH,* AUSTIN G.
More informationSevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
REVIEW Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis Vincenzo Savica 1,2 Domenico Santoro 1 Paolo Monardo 2 Agostino Mallamace 1 Guido
More informationCoronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients
Kidney International, Vol. 65 (2004), pp. 1790 1794 Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients ALI A. HAYDAR, ADRIAN COVIC, HELEN COLHOUN, MICHAEL RUBENS,
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationMarie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche
Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude
More informationVelphoro (sucroferric oxyhydroxide)
STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Effect on mortality of elective parathyroid surgery in one hundred and three patients with chronic kidney disease : our experience. White Rose Research Online URL for this
More informationThe natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients
Nephrol Dial Transplant (2006) 21: 1407 1412 doi:10.1093/ndt/gfl021 Advance Access publication 27 February 2006 Brief Report The natural history of coronary calcification progression in a cohort of nocturnal
More informationSevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
Kidney International, Vol. 62 (2002), pp. 245 252 Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients GLENN M. CHERTOW, STEVEN K. BURKE, PAOLO RAGGI, for
More informationMeasurement of vascular calcification using CT fistulograms
Nephrol Dial Transplant (2007) 22: 484 490 doi:10.1093/ndt/gfl621 Advance Access publication 7 November 2006 Original Article Measurement of vascular calcification using CT fistulograms Nigel D. Toussaint
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationPhosphate binder therapy for attainment of K/DOQI TM bone metabolism guidelines
Kidney International, Vol. 68, Supplement 96 (2005), pp. S7 S14 Phosphate binder therapy for attainment of K/DOQI TM bone metabolism guidelines CARLES R. NOLAN University of Texas ealth Sciences Center
More informationComplications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease
Med Clin N Am 89 (2005) 549 561 Complications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease Shona Pendse, MD, Ajay K. Singh, MB, MRCP(UK)* Renal Division, Brigham and
More information( 1) Framingham Heart
( 1) ( 1) Framingham Heart Study [1] 1. (Am J Kidney Dis. 45: 223-232, 2005) 96 19 1 17 Framingham Heart Study ( 1) American Heart Association (1) (2) (3) (4) [2] (GFR) [3] ARIC [4] Cardiovascular Health
More informationJ Am Soc Nephrol 15: , 2004
J Am Soc Nephrol 15: 770 779, 2004 Calcium, Phosphate, and Parathyroid Hormone Levels in Combination and as a Function of Dialysis Duration Predict Mortality: Evidence for the Complexity of the Association
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationAlink between secondary hyperparathyroidism and
Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study Yelena Slinin,* Robert N. Foley,* and Allan J. Collins* *United States Renal
More informationLanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding
Renal Failure, 34(3): 263 270, (2012) Copyright Informa Healthcare USA, Inc. ISSN 0886-022X print/1525-6049 online DOI: 10.3109/0886022X.2011.649657 Lanthanum Carbonate Reduces Urine Phosphorus Excretion:
More informationSevelamer Decreases Serum Uric Acid Concentration through Adsorption of Uric Acid in Maintenance Hemodialysis Patients
ORIGINAL ARTICLE Sevelamer Decreases Serum Uric Acid Concentration through Adsorption of Uric Acid in Maintenance Hemodialysis Patients Iwao Ohno 1, Yuichiro Yamaguchi 1, Hajime Saikawa 1, Daijiro Uetake
More informationAmol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through
Research Article ISSN: 0974-6943 Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through www.jpronline.info Comparison of efficacy and safety of Cinacalcet versus Calcitriol
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationLevel 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor
chapter 4.1 http://www.kidney-international.org & 2009 KDIGO Chapter 4.1: Treatment of CKD MBD targeted at lowering high serum phosphorus and maintaining serum calcium ; doi:10.1038/ki.2009.192 Grade for
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationTreatment Options for Chronic Kidney
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition
More informationCardiovascular mortality is up to 20 times more common
Impact of Cardiovascular Calcification in Nondialyzed Patients after 24 Months of Follow-up Renato Watanabe, Marcelo M. Lemos, Silvia R. Manfredi, Sérgio A. Draibe, and Maria Eugênia F. Canziani Department
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationBenefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials
Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C. Craig, MBChB, PhD, Grahame J.
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 01 June 2007 Product Name : Renagel Procedure No: EMEA/H/C/000254/II/56 SCIENTIFIC DISCUSSION 1/11 1. Introduction Renagel (sevelamer), a non-absorbed, calcium and metal-free
More informationA Comparison of Calcium-Based Phosphorus Binders for Patients with Chronic Kidney Disease
A Comparison of Calcium-Based Phosphorus Binders for Patients with Chronic Kidney Disease Michael Emmett, MD The author is with the Department of Internal Medicine, Baylor University Medical Center, Dallas,
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationPhosphate excess has been implicated in the substantial
Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease Bryan Kestenbaum,* Joshua N. Sampson, Kyle D. Rudser, Donald J. Patterson, Stephen L. Seliger, Bessie Young, Donald J.
More informationComparative Effectiveness of Calcium-Containing Phosphate Binders in Incident U.S. Dialysis Patients
Article Comparative Effectiveness of -Containing hosphate Binders in Incident U.S. Dialysis atients Wolfgang C. Winkelmayer,* Jun Liu,* and Bryan Kestenbaum Summary Background and objectives Few studies
More informationThe New England Journal of Medicine CORONARY-ARTERY CALCIFICATION IN YOUNG ADULTS WITH END-STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
CORONARY-ARTERY CALCIFICATION IN YOUNG ADULTS WITH END-STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS WILLIAM G. GOODMAN, M.D., JONATHAN GOLDIN, M.D., PH.D., BEATRIZ D. KUIZON, M.D., CHUN YOON, M.D.,
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationOPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura
www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance
More informationThe Egyptian Journal of Hospital Medicine (October 2013) Vol.53;Page
The Egyptian Journal of Hospital Medicine (October 2013) Vol.53;Page 752 762 Low Dose Nicotinamide as an Adjunctive Therapy to Calcium Carbonate for Control of Hyperphosphatemia in Hemodialysis Patients
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationCoronary calcification in hemodialysis patients: The contribution
Kidney International, Vol. 67 (2005), pp. 1576 1582 Coronary calcification in hemodialysis patients: The contribution of traditional and uremia-related risk factors DANIELA VEITBARRETO,FELLYPE CARVALHO
More informationLiterature Scan: Phosphate Binders
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAssociation of pelvic arterial calcification with arteriovenous thigh graft failure in haemodialysis patients
Nephrol Dial Transplant (2004) 19: 2564 2569 doi:10.1093/ndt/gfh414 Advance Access publication 27 July 2004 Original Article Association of pelvic arterial calcification with arteriovenous thigh graft
More informationSurvival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy
The new england journal of medicine original article Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy Ming Teng, M.D., Myles Wolf, M.D., M.M.Sc., Edmund Lowrie, M.D.,
More informationRandomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients
Article Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients Rudolf P. Wüthrich,* Michel Chonchol, Adrian Covic, Sylvain Gaillard, Edward Chong, and James A. Tumlin
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationYoung patients with end-stage renal disease (ESRD) suffer
Advanced Coronary and Carotid Arteriopathy in Young Adults With Childhood-Onset Chronic Renal Failure Jun Oh, MD; Rainer Wunsch, MD; Martin Turzer, BSc; Malte Bahner, MD; Paolo Raggi, MD; Uwe Querfeld,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationNew Medicines Profile. December 2013 Issue No. 13/04. Colestilan
New Medicines Profile December 2013 Issue. 13/04 Concise evaluated information to support the managed entry of new medicines in the NHS Summary (BindRen ) is an oral, non-absorbed, non-calcium, nonmetallic
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationSurvival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients
http://www.kidney-international.org & 6 International Society of Nephrology original article Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients K Kalantar-Zadeh,,
More informationLong-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism
Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism Kazunori Nakayama 1, 2, Kazushi Nakao 1, 2, Yuji Takatori 1,
More informationSecondary hyperparathyroidism in dialysis patients
Secondary hyperparathyroidism in dialysis patients ( a critical approach of pharmacological treatments) Dominique JOLY Néphrologie Hôpital NECKER, Paris DFG Finn WF. J Am Soc Nephrol. 24;15:271A. Ca ++
More informationThe hart and bone in concert
The hart and bone in concert Piotr Rozentryt III Department of Cardiology, Silesian Centre for Heart Disease, Silesian Medical University, Zabrze, Poland Disclosure Research grant, speaker`s fee, travel
More informationNephrology. ABC Fax In-Depth Topic Review. Sharon M. Moe a. Tilman B.
American Journal of Nephrology In-Depth Topic Review Am J Nephrol 2003;23:369 379 DOI: 10.1159/000073945 Received: August 4, 2003 Accepted: August 22, 2003 Published online: October 9, 2003 Management
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationC ardiovascular disease (CVD) and stroke are the main causes of morbidity and
Original Article DOI: 10.22088/cjim.9.4.347 Risk factors associated with aortic calcification in hemodialysis patients Alireza PeyroShabani 1 Mehrdad Nabahati (MD) 2, 3 MohammadAli Saber Sadeghdoust (MD)
More informationThe Role of Daily Dialysis in the Control of Hyperphosphatemia
Artículo de Actualización The Role of Daily Dialysis in the Control of Hyperphosphatemia Steven G. Achinger, Juan Carlos Ayus* *Division of Nephrology, University of Texas Health Science Center San Antonio,
More informationTitle:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients
Author's response to reviews Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Authors: Da Shang (sdshangda@163.com) Qionghong
More informationThe Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism
J Am Soc Nephrol 13: 1017 1024, 2002 The Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism WILLIAM G. GOODMAN,* GERALD A. HLADIK,
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationMonth/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNephrology Unit- CHU Liège- Ulg- Belgium
Are the complications of arteriovenous fistulas associated with an abnormal Ankle-Brachial Index in Hemodialysis? A 4y study P. Xhignesse, A. Saint-Remy, B. Dubois, JC. Philips, JM. Krzesinski Nephrology
More informationPREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL
PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL DR. ANNE MUGERA The Problem Chronic Kidney disease is a worldwide
More informationPathogenesis and Treatment of Renal Osteodystrophy
Proceedings Blood Purif 2003;21:318 326 DOI: 10.1159/000072552 Eduardo Slatopolsky a Esther Gonzalez b Kevin Martin b a Renal Division, Washington University School of Medicine, St. Louis, Mo., and b Division
More informationDeterminants of coronary artery calcification in maintenance hemodialysis patients
1 Determinants of coronary artery calcification in maintenance hemodialysis patients Yoshiko Nishizawa, MD 1,2, Sonoo Mizuiri, MD, PhD 2, Noriaki Yorioka, MD, PhD 3, Chieko Hamada MD, PhD 1,Yasuhiko Tomino
More informationGuidelines and new evidence on CKD - MBD treatment
Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,
More informationVascular calcification and cardiovascular function in chronic kidney disease
NDT Advance Access published November 1, 2005 Nephrol Dial Transplant (2005) 1 of 8 doi:10.1093/ndt/gfi236 Original Article Vascular calcification and cardiovascular function in chronic kidney disease
More informationSince its first application as a treatment for end-stage
Dialysis Session Length ( t ) as a Determinant of the Adequacy of Dialysis Manjula Kurella and Glenn M. Chertow Several studies have shown an association between the hemodialysis session length (the t
More informationPulmonary Hypertension and Predisposing Factors in Patients Receiving Hemodialysis
Dialysis Pulmonary Hypertension and Predisposing Factors in Patients Receiving Hemodialysis Seyed Alijavad Mousavi, 1 Mitra Mahdavi-Mazdeh, 2 Hooman Yahyazadeh, 1 Mitra Azadi, 3 Nahid Rahimzadeh, 4 Hajar
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson-Zachrisson, 3
More information